Benjamin Hyatt, MD
Gastroenterology · Worcester, MANPI 1477518678
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,854 of the $135,044 with a category attached, or 67.3%. Johnson & Johnson accounts for 85.0% of it on its own, with 36 other manufacturers making up the rest. 2025 is the largest year on record at $68,026, more than ten times the $875 reported in 2019. Among gastroenterology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 679 payments — averaging $198.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$115K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- E.r. Squibb & Sons, L.L.C.$4K
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Ardelyx, Inc.$1K
- plus $6K from 31 others
What the payments were for
- Consulting fees$20,56315%
- Speaking & faculty fees$90,85467%
- Travel & lodging$7,5196%
- Food & beverage$16,03612%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 146 | $114,849 |
| Takeda Pharmaceuticals U.S.A., Inc. | 72 | $5,539 |
| E.r. Squibb & Sons, L.L.C. | 2 | $3,684 |
| AbbVie(2 entities) | 110 | $2,337 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 82 | $1,438 |
| Ardelyx, Inc. | 12 | $1,427 |
| Pfizer | 55 | $992 |
| QOL Medical, LLC | 35 | $874 |
| Bristol Myers Squibb | 24 | $586 |
| Gilead | 20 | $521 |
| Regeneron Healthcare Solutions, Inc. | 11 | $337 |
| Madrigal Pharmaceuticals | 9 | $323 |
| Ferring Pharmaceuticals Inc. | 14 | $259 |
| Sanofi | 9 | $246 |
| Phathom Pharmaceuticals, Inc. | 19 | $235 |
| Ipsen Biopharmaceuticals, Inc | 7 | $210 |
| Ironwood Pharmaceuticals, Inc | 8 | $198 |
| Janssen Scientific Affairs, LLC | 1 | $127 |
| Celltrion USA Inc. | 6 | $103 |
| Aimmune Therapeutics, Inc. | 6 | $98 |
| Fresenius Kabi USA, LLC | 5 | $89 |
| Lilly USA, LLC | 4 | $74 |
| Stryker | 1 | $69 |
| Braintree Laboratories, Inc. | 3 | $68 |
| Neuraxis, Inc. | 1 | $54 |
| Intercept Pharmaceuticals, Inc. | 2 | $47 |
| Micro-tech Endoscopy USA, Inc. | 2 | $33 |
| Merck | 2 | $31 |
| Boehringer Ingelheim | 1 | $31 |
| Boston Scientific | 1 | $30 |
| Fujifilm Healthcare Americas Corporation | 1 | $26 |
| UCB, Inc. | 2 | $25 |
| Organon | 2 | $19 |
| Echosens North America, Inc. | 1 | $18 |
| Sandoz | 1 | $16 |
| Medtronic | 1 | $15 |
| Capsovision, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$135,044 in reported general payments places this provider in the 95th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 14 | $403,122 |
| CreonLipase/Protease/Amylase | 17 | $73,359 |
| Mesalamine | 32 | $34,776 |
| LinzessLinaclotide | 32 | $29,566 |
| MotegrityPrucalopride Succinate | 14 | $11,044 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 44 | $7,179 |
| Sucralfate | 47 | $4,792 |
| Entecavir | 12 | $3,857 |
| Ursodiol | 15 | $1,942 |
| CholestyramineCholestyramine (With Sugar) | 30 | $1,634 |
| Omeprazole | 117 | $1,559 |
| Colestipol Hcl | 25 | $1,358 |
| Pantoprazole Sodium | 77 | $1,341 |
| Esomeprazole Magnesium | 27 | $1,319 |
| Famotidine | 101 | $1,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $114,849 | $403,12214 claims |
| AbbVieCreon, Linzess | $2,337 | $102,92549 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $5,539 | $11,04414 claims |
| Braintree Laboratories, Inc.Sutab | $68 | $7,17944 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 579 gastroenterology providers in Massachusetts.
Other gastroenterology in Worcester
- Neil MaryaWorcester$127K
- Curuchi AnandWorcester$117K
- Abbas RupawalaWorcester$74K
- Gustavo ChurrangoWorcester$51K
- Anita KrishnaraoWorcester$40K
- Hiroyuki AiharaBoston$728K
- Jessica AllegrettiBoston$696K
- John LeungBoston$682K
- Ramnik XavierBoston$567K
- Adam CheifetzBoston$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.